Aurora Science

InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

Peptomyc is a biotechnology company dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a critical factor in cancer cell survival. Founded in December 2014, the company is rooted in over two decades of research by Dr. Soucek on Omomyc, recognized as the most effective direct Myc inhibitor. With cancer incidence surpassing 14 million cases annually and projected to rise significantly, conventional treatments often fail due to resistance. Peptomyc's approach seeks to inhibit Myc, which is deregulated in most human cancers and plays an essential role in tumor evolution. This strategic focus on Myc represents a promising avenue in cancer therapy, particularly for challenging cases such as lung, breast, and brain tumors, offering the potential to enhance patient survival rates where existing therapies may fall short.